BANK VONTOBEL/CALL/NOVO NORDISK ADR B/145/0.1/20.09.24 | Delayed Deutsche Boerse AG 09:33:14 27/06/2024 BST | ||
| 0.81 EUR | -2.41% |
|
| Current month | +76.60% | ||
| 1 month | +43.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 0.81 | -2.41% |
| 26/06/24 | 0.83 | -15.31% |
| 25/06/24 | 0.98 | +38.03% |
| 24/06/24 | 0.71 | -2.74% |
| 21/06/24 | 0.73 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 27, 2024 at 09:33 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD0HC0 |
| ISIN | DE000VD0HC04 |
| Date issued | 16/02/2024 |
| Strike | 145 $ |
| Maturity | 20/09/2024 (86 Days) |
| Parity | 10 : 1 |
| Emission price | 0.42 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.06 € |
|---|---|
| Lowest since issue | 0.29 € |
| Spread | 0.02 € |
| Spread % | 2.41% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,007
DKK
Average target price
937.9
DKK
Spread / Average Target
-6.86%
- Stock Market
- Warrants
- Warrant
